Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis by Pohjantähti-Maaroos, Hanna et al.
RESEARCH ARTICLE Open Access
Erectile dysfunction, physical activity and
metabolic syndrome: differences in markers of
atherosclerosis
Hanna Pohjantähti-Maaroos
1,2,3*, Ari Palomäki
1,2 and Juha Hartikainen
3
Abstract
Background: Erectile dysfunction (ED), impaired arterial elasticity, elevated resting heart rate as well as increased
levels of oxidized LDL and fibrinogen associate with future cardiovascular events. Physical activity is crucial in the
prevention of cardiovascular diseases (CVD), while metabolic syndrome (MetS) comprises an increased risk for CVD
events. The aim of this study was to assess whether markers of subclinical atherosclerosis are associated with the
presence of ED and MetS, and whether physical activity is protective of ED.
Methods: 57 MetS (51.3 ± 8.0 years) and 48 physically active (PhA) (51.1 ± 8.1 years) subjects participated in the
study. ED was assessed by the International Index of Erectile Function (IIEF) questionnaire, arterial elasticity by a
radial artery tonometer (HDI/PulseWave™ CR-2000) and circulating oxLDL by a capture ELISA immunoassay.
Fibrinogen and lipids were assessed by validated methods. The calculation of mean daily energy expenditure of
physical exercise was based on a structured questionnaire.
Results: ED was more often present among MetS compared to PhA subjects, 63.2% and 27.1%, respectively (p <
0.001). Regular physical exercise at the level of > 400 kcal/day was protective of ED (OR 0.12, 95% CI 0.017-0.778, p
= 0.027), whereas increased fibrinogen (OR 4.67, 95% CI 1.171-18.627, p = 0.029) and elevated resting heart rate
(OR 1.07, 95% CI 1.003-1.138, p = 0.04) were independently associated with the presence of ED. In addition, large
arterial elasticity (ml/mmHgx10) was lower among MetS compared to PhA subjects (16.6 ± 4.0 vs. 19.6 ± 4.2, p <
0.001), as well as among ED compared to non-ED subjects (16.7 ± 4.6 vs. 19.0 ± 3.9, p = 0.008). Fibrinogen and
resting heart rate were highest and large arterial elasticity lowest among subjects with both MetS and ED.
Conclusions: Markers of subclinical atherosclerosis associated with the presence of ED and were most evident
among subjects with both MetS and ED. Thus, especially MetS patients presenting with ED should be considered
at high risk for CVD events. Physical activity, on its part, seems to be protective of ED.
Trial registration: ClinicalTrials.gov NCT01119404
Background
Atherosclerosis begins with oxidation of LDL particles
in the arterial wall [1]. Oxidatively modified LDL
(oxLDL) damages the endothelium of the artery - a
pathophysiology similar to that of vascular erectile dys-
function (ED) [1,2]. As a result, the elasticity of the
arteries deteriorates. Impaired arterial elasticity and
increased levels of circulating oxLDL as well as elevated
fibrinogen and resting heart rate associate with subclini-
cal atherosclerosis and increased risk of cardiovascular
disease (CVD) events [3-8].
Besides similar pathophysiology, ED and CVD share
same risk factors [9]. In addition, a high prevalence of
both silent and clinical CVD has been reported among
ED patients [9,10]. ED has also been reported as an
independent predictor of incident CVD [11,12]. Since
ED often precedes CVD symptoms from other vascular
beds, it is thought to be an early clinical manifestation
of systemic atherosclerosis [9,13]. * Correspondence: hanna.pohjantahti-maaroos@kuh.fi
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tion of CVD. Sedentary lifestyle, on its part, predisposes
to metabolic syndrome (MetS), a clustering of metabolic
disorders; visceral obesity, hypertension, dyslipidaemia
and insulin resistance or diabetes [14]. MetS comprises
a high risk for CVD events even in the absence of dia-
betes [15]. Mechanisms that link MetS to increased
CVD risk are, however, incompletely understood.
In the present study we assessed arterial elasticity, cir-
culating oxLDL levels, fibrinogen and resting heart rate
among MetS and physically active (PhA) subjects. The
aim was to study whether these markers of subclinical
atherosclerosis associate with ED and MetS, and
whether physical activity is protective of ED.
Methods
Subjects
120 men with MetS and 80 physically active (PhA) men
participating in the Hämeenlinna Metabolic Syndrome
research program (HMS) were recruited in the study.
MetS was diagnosed according to National Cholesterol
Education Program (NCEP) criteria [16]. We inter-
viewed the subjects on their medical history and lifestyle
habits. Participation of a PhA subject was accepted if he
exercised more than three times a week and 30 minutes
per exercise on a regular basis without chest pain, dys-
pnea or fatigue, and did not fulfil the criteria of MetS.
Exclusion criteria were non-specific beta-blocker medi-
cation and suspected non-vascular ED. Suspicion of
non-vascular ED was based on patient records and
patients’ self-report during in the presence of possible
psychogenic, urogenital, neurological or endocrinological
cause for ED. Diagnoses of diabetes, hypertension and
CVD were based on patients’ report on previously diag-
nosed diseases, patient records and the use of antihyper-
glycemic, antihypertensive or antianginal medication.
Positive family history of CVD was considered among
subjects reporting previously diagnosed CVD in a first
degree relative.
Subjects filled in a structured questionnaire on their
average amount, type and intensity of leisure time physi-
cal exercise per week. The compendium of physical
activities and subjects’ self-rated intensity levels were
used in estimating the metabolic equivalent (MET)
values [17]. The energy expenditure of mean daily physi-
cal exercise was calculated in kilocalories by multiplying
the MET value and exercise times per week and mean
duration of exercise in hours and person’sw e i g h ti n
kilograms and finally dividing it by seven. Physical activ-
ity level was considered low if mean daily energy expen-
diture of physical exercise was < 200 kcal/day, moderate
if 200-400 kcal/day and high if > 400 kcal/day. In addi-
tion, waist circumference, height, weight and blood pres-
sure were measured.
Each study subject signed an informed consent. The
ethics committee of the Kanta-Häme Hospital District
in Finland approved the study which was carried out in
compliance with the Helsinki Declaration.
International Index of Erectile Dysfunction (IIEF)
questionnaire
Subjects filled in the IIEF questionnaire [18]. The sum
of the questions 1-5 and 15 was calculated to assess the
presence of ED. Subjects with maximal score of 30 were
considered to have normal erectile function and subjects
with score of ≤2 5 ,w e r ec o n s i d e r e dt oh a v eE D .T o
ensure that the study subjects truly had either comple-
tely normal or impaired erectile function, subjects with
IIEF score 26 to 29 were excluded. The question num-
ber 15 (how do you rate your confidence that you can
get and keep your erection?) was used to assess the pre-
sence of erectile function in men reporting lack of sex-
ual activity in questions 1-5. A subject reporting very
high confidence in the question number 15, was consid-
ered to have normal erectile function. Those reporting
very low to medium confidence were considered to have
ED, and those reporting high confidence were excluded.
Arterial elasticity and laboratory procedures
Arterial elasticity was assessed by a non-invasive radial
artery tonometer (HDI/PulseWave™CR-2000) in a
semi-sitting position. Arterial tonometer uses a modified
Windkessel method to estimate systemic large (C1) and
small (C2) arterial elasticity [3]. C1 identifies the elasti-
city of the aorta and other large arteries, C2 the elasti-
city and endothelial function of the microvascular
circulation. Indices determined by this validated method
correlate tightly with those determined invasively [3,19].
In addition, C1 seems to correlate significantly with
MRI-determined aortic distensibility, whereas C2 corre-
late with endothelial function assessed by flow-mediated
dilation [20,21]. In addition, elasticity indices assessed
by the HDI/Pulsewave™CR-2000 have been reported
reliable and repeatable over a short and long period of
observation [19,22]. The reference values depend on age
and gender. Among men aged 50-59 years, C1 above 11
ml/mmHgx10 and C2 above 7 ml/mmHgx100 are con-
sidered normal.
Arterial elasticity indices were assessed automatically by
the tonometer as a mean of five most similar pulse waves
appearing during 30 seconds of measurement. Mean of
four consecutive measurements was assessed. Blood pres-
sure and resting heart rate were automatically measured
by the CR-2000 during the elasticity measurement.
Intraindividual CV% was 9.0% for C1 and 8.8% for C2.
Same experienced nurse performed all measurements.
Plasma levels of oxLDL were determined as duplicates
by a capture ELISA immunoassay (Mercodia AB,
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as in the assays by Holvoet et al [6]. CV% of oxLDL
measurement was 7.7%. Fibrinogen and lipids were
assessed by validated methods.
Statistical methods
Statistics were analyzed with SPSS for Windows 17.0.
Data are presented as mean ± SD if not mentioned
otherwise. A probability value < 0.05 was considered sta-
tistically significant.
Student’s T-test was used in assessing the differences
between subjects with ED and normal erectile function
as well as between MetS and PhA subjects in case of
normality. Mann Whitney U-test was used in case of
non-normality. ANOVA was used to analyze the
adjusted p values for differences in two-dimensional
variables as well as in four-dimensional variables in case
of normality. Bonferroni post hoc analysis was used for
multiple comparisons regarding fibrinogen, resting heart
rate and arterial elasticity. The differences were adjusted
for age, smoking, blood pressure, diabetes, CVD, and
LDL cholesterol. Kruskall-Wallis test was used in case
of non-normality. Differences in categorical values were
calculated by c
2 test. Univariate and multivariate ana-
lyses of the associations between risk factors and mar-
kers of CVD and the presence of ED were conducted
with binary logistic regression model. Traditional CVD
risk factors and assessed markers of subclinical athero-
sclerosis without strong correlation with each other
were included as covariates in the multivariate analysis.
Multivariate analysis was conducted with the enter
method by removing covariates without association to
ED one by one. The result was verified with the forward
conditional method and adjusted for the use of medica-
tions. OR, 95% CI and p values for covariates in the uni-
variate analyses and for significant covariates in the
adjusted multivariate analysis, as well as Nagelkerke R
2
of the final model are presented.
Results
Fifty-seven MetS and 48 PhA subjects without exclusion
criteria completed the IIEF questionnaire. Ten men with
MetS and four PhA men reported lack of sexual activity.
All except one of these 14 men were diagnosed with ED
according to the question number 15. Altogether ten
men with MetS had previously diagnosed CVD. There
were four patients with coronary artery disease, three
with cerebrovascular disease, two with coronary artery
and cerebrovascular disease and one with coronary
artery and peripheral artery disease. ED was more often
present among MetS compared to PhA subjects, 36
(63.2%) and 13 (27.1%), respectively (p < 0.001) (Figure
1). Clinical characteristics and medications of the study
groups are presented in Table 1 and clinical chemistry
i nT a b l e2 .N o n eo ft h es t u d ys u b j e c t su s e dP D E 5 -
inhibitors.
There was an evident difference in the amount of daily
physical exercise between PhA and MetS subjects, 496.7
±2 8 6 . 9k c a l / d a yvs. 176.3 ± 210.8 kcal/day, respectively
(p < 0.001). In addition, subjects with normal erectile
function were physically more active compared to sub-
jects with ED, 395.3 ± 319.5 kcal/day vs. 235.7 ± 237.3
kcal/day, respectively (p = 0.005). Physical activity of the
study groups is presented in Table 1.
Fibrinogen was lower among PhA compared to MetS
subjects, 2.90 ± 0.47 g/L vs. 3.53 ± 0.82 g/L, respectively
(p < 0.001). Furthermore, fibrinogen levels were lower
among subjects with normal erectile function compared
to those with ED, 3.00 ± 0.50 g/L vs. 3.51 ± 0.89 g/L,
respectively (p = 0.001). Fibrinogen levels were 2.91 ±
0.4 g/L among PhA subjects without ED, 2.87 ± 0.6 g/L
among PhA subjects with ED, 3.16 ± 0.6 g/L among
MetS subjects without ED, and 3.74 ± 0.9 g/L among
MetS subjects with ED (Figure 2). There were no signifi-
cant differences in oxLDL levels between any of the
groups (Table 2).
Resting heart rate was lower among PhA compared to
MetS subjects, 52.5 ± 9.6 beats/min vs. 65.1 ± 10.0
beats/min (p < 0.001). The difference remained signifi-
cant after adjustment for age and selective b-blocker
medication (p < 0.001). Resting heart rate was also
lower among subjects with normal erectile function,
compared to those with ED, 55.6 ± 9.8 beats/min vs.
63.5 ± 12.3 beats/min (p = 0.001). After adjustment for
age and selective b-blocker medication, the difference
remained significant (p = 0.001). Resting heart rate was
51.9 ± 9.0 beats/min among PhA subjects without ED,
54.3 ± 11.4 beats/min among PhA subjects with ED,
p < 0.001
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Figure 1 Prevalence of erectile dysfunction (ED) among
metabolic syndrome (MetS) and physically active (PhA)
subjects.
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Page 3 of 962.3 ± 7.6 beats/min among MetS subjects without ED,
and 66.8 ± 11.0 beats/min among MetS subjects with
ED (Figure 3).
PhA subjects had better large arterial elasticity (C1)
compared to MetS subjects, 19.6 ± 4.2 ml/mmHgx10
and 16.6 ± 4.0 ml/mmHgx10, respectively (p < 0.001).
There was no difference between the groups in small
arterial elasticity (C2). Subjects with normal erectile
function had better C1 compared to those with ED, 19.0
± 3.9 ml/mmHgx10 and 16.7 ± 4.6 ml/mmHgx10,
respectively (p = 0.008). Also C2 was better among
those with normal erectile function compared to those
w i t hE D ,7 . 5±3 . 2m l / m m H g x 1 0 0a n d6 . 2±3 . 0m l /
mmHgx100, respectively (p = 0.035). The difference in
C1 remained significant even after adjustment for age (p
= 0.035) and the use of selective b-blockers (p = 0.026).
After the same adjustment the difference in C2 did not
remain significant. C1 was 19.7 ± 4.1 ml/mmHgx10
Table 1 Clinical characteristics of study subjects
PhA MetS
no ED ED no ED ED p
(n = 35) (n = 13) (n = 21) (n = 36)
Age
1, years 49.4 ± 7.5 56.9 ± 6.7 45.9 ± 4.6 54.1 ± 8.2 < 0.001
CVD in family, n (%) 18 (51.4%) 9 (69.0%) 1 (52.3%) 18 (50.0%) NS
Diagnosed CVD
b, n (%) 0 (0%) 0 (0%) 3 (14.3%) 7 (19.4%) < 0.05
Diabetics
2,a, n (%) 0 (0%) 0 (0%) 7 (33.3%) 19 (52.8%) < 0.001
Hypertension
2,a, n (%) 1 (2.9%) 3 (23.1%) 11 (52.4%) 20 (55.6%) < 0.001
ASA
c, n (%) 4 (11.4%) 0 (0%) 5 (23.8%) 10 (27.8%) NS
b1-blocker
2,a, n (%) 0 (0%) 1 (7.7%) 4 (19.0%) 15 (41.7%) < 0.001
ACE-inhibitor, n (%) 1 (2.9%) 2 (15.4%) 2 (9.5%) 4 (11.1%) NS
ATR-blocker
a, n (%) 0 (0%) 0 (0%) 5 (23.8%) 11 (30.6%) < 0.01
Ca-blocker, n (%) 0 (0%) 1 (7.7%) 1 (4.8%) 3 (8.3%) NS
Diuretic
b, n (%) 0 (0%) 1 (7.7%) 4 (19.0%) 8 (22.2%) < 0.05
Statin
b, n (%) 4 (11.4%) 2 (15.4%) 7 (33.3%) 14 (38.9%) < 0.05
Smoking
b < 0.01
-current, n (%) 1 (2.9%) 0 (0%) 5 (23.8%) 6 (16.7%)
-former, n (%) 11 (31.4%) 6 (46.2%) 10 (47.6%) 18 (50.0%)
-never, n (%) 23 (65.7%) 7 (53.8%) 6 (28.6%) 12 (33.3%)
Physical activity
2,a, kcal/day 506.9 ± 300 467.1 ± 256 209.4 ± 265 156.4 ± 172 < 0.001
Alcohol intake
b, g/day 7.8 ± 6.0 6.0 ± 4.3 15.0 ± 13.5 20.1 ± 22.8 < 0.01
BMI
2,a, kg/m
2 23.8 ± 2.0 24.6 ± 3.0 32.7 ± 4.5 32.0 ± 4.8 < 0.001
Waist circumf.
2,a, cm 88.6 ± 7.1 90.8 ± 8.9 113.5 ± 10.5 114.8 ± 13.3 < 0.001
SBP
3,a, mmHg 127.2 ± 9.2 126.9 ± 11.2 136.5 ± 12.2 139.8 ± 16.5 < 0.001
DBP
a, mmHg 73.9 ± 6.7 74.5 ± 5.6 82.1 ± 7.4 81.7 ± 8.8 < 0.001
1-3 p value for the difference between men with and without ED:
1 p < 0.001,
2 p < 0.01,
3 p < 0.05. NS if not mentioned.
a-c p value for the difference between PhA and MetS subjects:
a p < 0.001,
b p < 0.01,
c p < 0.05. NS if not mentioned.
ASA - acetylsalicylic acid; ATR - angiotensin receptor; BMI - body mass index; CVD - cardiovascular disease; DBP - diastolic blood pressure; ED - erectile
dysfunction; MetS - metabolic syndrome; PhA - physically active; SBP - systolic blood pressure
Table 2 Clinical chemistry of study subjects
PhA MetS
no ED ED no ED ED p
(n = 35) (n = 13) (n = 21) (n = 36)
Cholesterol, mmol/L 5.27 ± 0.7 5.33 ± 0.8 5.26 ± 1.1 5.30 ± 1.6 NS
LDL-C, mmol/L 3.47 ± 0.7 3.32 ± 0.9 3.24 ± 0.9 3.21 ± 1.0 NS
HDL-C
3,a, mmol/L 1.61 ± 0.3 1.81 ± 0.4 1.20 ± 0.2 1.16 ± 0.3 < 0.001
Triglycerides
3,a, mmol/L 0.94 ± 0.5 0.86 ± 0.4 2.49 ± 1.4 3.19 ± 5.1 < 0.001
OxLDL, U/L 71.8 ± 21.4 75.5 ± 35.5 78.5 ± 40.1 80.8 ± 33.5 NS
Glucose
2,a, mmol/L 5.49 ± 0.4 5.59 ± 0.6 6.54 ± 1.0 6.99 ± 2.2 < 0.001
HbA1C
2,a,% 5.61 ± 0.2 5.60 ± 0.2 6.03 ± 0.6 6.47 ± 1.2 < 0.001
ED - erectile dysfunction; HbA1C - glycosylated haemoglobin; HDL-C - high density lipoprotein cholesterol; LDL-C - low density lipoprotein cholesterol; MetS -
metabolic syndrome; OxLDL - oxidized LDL; PhA - physically active. Upper indices for p values as in Table 1.
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mmHgx10 among PhA subjects with ED, 17.8 ± 3.1 ml/
mmHgx10 among MetS subjects without ED and 15.9 ±
4.4 ml/mmHgx10 among MetS subjects with ED (Figure
4). C2 was 7.2 ± 2.7 ml/mmHgx100, 6.7 ± 3.3 ml/
mmHgx100, 8.1 ± 3.9 ml/mmHgx100, and 6.0 ± 2.9 ml/
mmHgx100, respectively (NS).
Results of the univariate analyses are presented in Table
3. MetS associated with the presence of ED even after
adjustment for age, physical activity, smoking and total
cholesterol (OR = 5.83, 95% CI 1.730-19.618, p = 0.004).
The association of MetS and ED did not remain significant
after adjustment for individual MetS components. Of the
markers of subclinical atherosclerosis, C1 and C2 were
negatively and fibrinogen and resting heart rate positively
associated with the presence of ED. The association
between ED and C1 remained significant after adjustment
for age (p = 0.047). OxLDL levels did not associate with
the presence of ED.
In the multivariate analysis among all study subjects,
age, fibrinogen and resting heart rate were directly and
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Figure 2 Fibrinogen levels (g/L) between the study groups (n =
105). Mean ± SEM is presented. P values after adjustment for age,
smoking, blood pressure, established CVD, diabetes and LDL
cholesterol,
a p < 0.001,
b p < 0.01,
c p < 0.05.
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Figure 3 Resting heart rate (beats/min) between the study
groups (n = 105). Mean ± SEM is presented. P values after
adjustment for age, smoking, blood pressure, established CVD,
diabetes and LDL cholesterol,
b p < 0.01,
c p < 0.05.
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Figure 4 Large arterial elasticity (C1, ml/mmHgx10) between
the study groups (n = 105). Mean ± SEM is presented. After
adjustment for age, smoking, blood pressure, established CVD,
diabetes and LDL cholesterol, the differences were not significant.
Table 3 Univariate analyses of risk factors and markers
of CVD as predictors of ED
Covariates OR 95% CI p
Age, years 1.14 1.066-1.209 < 0.001
Smoking, yes/no 1.16 0.349-3.871 NS
No of pack-years in smokers 1.06 1.005-1.116 0.031
Metabolic syndrome, yes/no 4.62 2.005-10.623 <0.001
Diabetes, yes/no 4.43 1.666-11.794 0.003
Hypertension, yes/no 3.24 1.387-7.587 0.007
CVD, yes/no 2.94 0.718-12.082 NS
Family history of CVD, yes/no 1.14 0.529-2.466 NS
BMI, kg/m
2 1.11 1.029-1.200 0.007
Physical activity, >400 vs. <200 kcal/day 0.22 0.082-0.561 0.002
HDL cholesterol, mmol/L 0.47 0.177-1.239 NS
LDL cholesterol, mmol/L 0.82 0.524-1.293 NS
Triglycerides, mmol/L 1.31 0.948-1.802 NS
Heart rate, beats/min 1.07 1.026-1.110 0.001
Fibrinogen, g/L 2.83 1.517-5.274 0.001
C1, ml/mmHgx10 0.88 0.794-0.969 0.010
C2, ml/mmHgx100 0.87 0.756-0.993 0.040
OxLDL, U/L 1.00 0.991-1.016 NS
BMI - body mass index; C1 -large arterial elasticity; C2 - small arterial elasticity;
CVD - cardiovascular disease; ED - erectile dysfunction; HDL -high density
lipoprotein; LDL - low density lipoprotein; OxLDL - oxidized low density
lipoprotein
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Page 5 of 9physical activity > 400 kcal/day inversely associated with
the presence of ED. These covariates remained signifi-
cant even after adjustment for traditional CVD risk fac-
tors and medications. Results of the adjusted
multivariate analysis are presented in Table 4.
In the multivariate analysis among MetS subjects only,
age (OR 1.23, 95% CI 1.09-1.39, p = 0.001) and fibrinogen
(OR 4.30 95% CI 1.21-15.2, p = 0.024) associated directly
and physical activity > 400 kcal/day (OR 0.05, 95% CI
0.004-0.65, p = 0.022) inversely with the presence of ED.
These covariates were significant predictors of ED even
after adjustment for smoking, diabetes, hypertension,
CVD, LDL and HDL cholesterol, triglycerides, BMI, family
history of CVD, and selective beta-blockers. Among PhA
subjects, age was the only significant predictor for the pre-
sence of ED (OR 1.16, 95% CI 1.04-1.30, p = 0.008).
Discussion
In the present study, physical activity was an indepen-
dent predictor of normal erectile function, whereas
increased fibrinogen and resting heart rate associated
independently with erectile dysfunction (ED). Impaired
large arterial elasticity (C1) was related to the presence
of ED as well as to the presence of MetS. Markers of
subclinical atherosclerosis were most evident among
subjects with both MetS and ED.
Previously physical activity has been found to
decrease the risk of ED and to improve sexual function
among those with established ED [23-25]. We found a
physical exercise level of > 400 kcal/day (i.e. > 2800
kcal/week) to associate independently with normal
erectile function in the analyses among all participants
as well as in the analyses restricted to MetS subjects
only. To our knowledge, this is the first study report-
ing the positive association between physical activity
and the presence of normal erectile function among
MetS.
PhA subjects presented often with normal erectile
function, whereas ED was highly prevalent among men
with MetS. Although we excluded subjects with submaxi-
mal IIEF score (score 26-29), still considered as normal
erectile function by the IIEF ,t h ep r e s e n c eo fE Da m o n g
PhA subjects was lower than expected [26]. Since obesity,
smoking and excess alcohol consumption have been
reported to associate with ED, and physical activity is
protective of ED, the overall healthy behaviour of the
PhA subjects must have contributed to the high existence
of normal erectile function among them [23-25,27].
In a recent study, MetS did not improve prediction of
CVD after adjustment for its individual components
[28]. In agreement, MetS per se was not an independent
predictor of ED in the present study. However, we
found a high prevalence of ED among MetS which has
also been reported previously [29]. The prevalence of
ED in the presence of diabetes or CVD is known to be
even higher [13,30]. Accordingly, there were more dia-
betics and CVD patients among those with MetS and
ED in the present study. Those with ED were also older
and more often hypertensive. Although subjects with
non-selective b-blocker medication were excluded, ED
subjects were more often on selective beta-blockers.
These factors may contribute to the higher number of
ED among MetS, and thereby to the findings of the
study. However, neither diabetes nor CVD were signifi-
cant predictors of ED in the multivariate analyses of the
present study. In addition, although the risk of sexual
dysfunction caused by b-blockers was low in a previous
systematic review of randomized trials, the results of the
present study were adjusted for the use of selective
beta-blockers [31]. Furthermore, also medications
r e p o r t e dt oi m p r o v es e x u a lf u n c t i o nw e r em o r eo f t e n
used among subjects with MetS and ED [32,33]. Thus,
the high use of medications among MetS seems rather
reflect the physical inactivity, obesity and concomitant
diseases among them, whereas the high prevalence of
ED among MetS may reflect the presence of underlying,
atherosclerotic disease.
We found increased fibrinogen levels among MetS
compared to PhA subjects which agrees with previous
studies [34,35]. Physical inactivity, obesity and smoking
have been reported to associate with increased fibrino-
gen levels, and thus may partly explain the difference
[35-37]. Fibrinogen levels were significantly higher also
in the presence of ED compared to the levels in the pre-
sence of normal erectile function in the analyses among
all participants but also among only MetS subjects. In
addition, increased fibrinogen levels associated with the
presence of ED independently of multiple other CVD
risk factors. There are no previous studies on the asso-
ciation of increased fibrinogen and ED among MetS.
However, our finding agrees with a previous study by
Vlachopoulos et al [38] reporting an independent pre-
dictive value of fibrinogen for the presence of ED both
among men with and without coronary artery disease.
Differing from the analyses restricted to MetS subjects
only, fibrinogen levels did not associate with the pre-
sence of ED among PhA subjects in the present study.
Table 4 Significant predictors of ED in the multivariate
analysis
Covariates OR 95% CI p
Age, years 1.19 1.072-1.322 0.001
Heart rate, beats/min 1.07 1.003-1.138 0.040
Physical activity, >400 vs. <200 kcal/day 0.12 0.017-0.778 0.027
Fibrinogen, g/L 4.67 1.171-18.627 0.029
The model was adjusted for smoking, CVD, diabetes, hypertension, family
history of CVD, BMI, HDL and LDL cholesterol, triglycerides and medications.
R
2 = 0.546.
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them, again reflecting the protective effect of healthy,
active lifestyle.
In line with previous publications we found a decrease
in large arterial elasticity (C1) among MetS compared to
PhA subjects [39,40]. In addition, impaired C1 asso-
ciated with the presence of ED. C1 was especially low
among men with both MetS and ED. There are also
previous reports on the connection between impaired
large arterial elasticity and ED [41,42]. However, in
these studies arterial elasticity was assessed by ultra-
sound or pulse-wave velocity measurements, not by the
pulse-wave analysis as in our previous and the present
study [43].
Endothelial dysfunction is believed to be a key
mechanism in the pathogenesis of ED as well as of
other atherosclerotic cardiovascular diseases [1,2]. In
studies assessing endothelial function by a regional mea-
surement of brachial flow-mediated dilation, endothelial
dysfunction associated with ED [44,45]. Small arterial
elasticity (C2), assessed in the present study, reflects the
systemic endothelial function of the microvascular circu-
lation but is also affected by alterations in the elastic
properties of the arterial wall [3]. Since C2 is not a mere
measurement of endothelial function, it may explain
why the association between C2 and the presence of ED
did not remain significant after adjustments.
Regular aerobic exercise may attenuate age-related
reduction in large arterial elasticity [46] and decrease
circulating oxLDL levels [47]. However, a significant
decrease in arterial elasticity and increase in oxidative
stress have been reported after exercise at a vigorous
level [48,49]. In our study, large arterial elasticity was
better among PhA compared to MetS subjects whereas
oxLDL levels were comparable between the groups. The
relatively small number of study subjects may explain
why the trend of increasing oxLDL in the presence of
MetS and ED remained non-significant. In addition,
although the inclusion criterion of minimum physical
exercise for the PhA subjects was relatively low, the
reported high level and intensity of exercise among
them might have influenced the results.
Previously MetS variables, such as hypertension, insu-
lin resistance and obesity, have been reported to associ-
ate with adrenergic overdrive [50]. Accompanying
elevation in resting heart rate increases peak blood flow
during diastole which in turn enhances pulsatile and
shear stress on the endothelium [51]. Resulting endothe-
lial dysfunction and loss of arterial elasticity may explain
the connection between elevated resting heart rate and
ED [51,52]. In agreement, resting heart rate was higher
among MetS compared to PhA subjects in the present
study, despite the higher use of beta-blockers among
MetS. In addition, heart rate was higher among ED
compared to non-ED subjects, being highest among
men with both MetS and ED. Since MetS subjects with
ED were physically most inactive, the elevated resting
heart rate was at least partly a consequence of their phy-
sical unfitness. However, elevated resting heart rate pre-
dicted the presence of ED independently of physical
activity, multiple other CVD risk factors, and beta-
blocker medication.
Because of the cross-sectional design, we cannot
make assumptions on the linkage between the mar-
kers of subclinical CVD and true CVD risk in the
future. However, the present study provides possible
pathophysiological links between erectile dysfunction
and increased cardiovascular risk among MetS. Sub-
j e c t sw i t hM e t Sa r ek n o w nt ob ea th i g hr i s kf o rC V D
[15]. ED, on its part, is considered as an early clinical
manifestation of systemic atherosclerosis [9,13]. Mar-
kers of subclinical atherosclerosis, assessed in the pre-
sent study, have previously been reported to associate
with increased risk of CVD events and mortality
[4,5,7,8]. Since increased fibrinogen and elevated rest-
ing heart rate as well as impaired arterial elasticity
were present among MetS compared to PhA subjects,
as well as among ED compared to non-ED subjects,
they may partly explain the increased CVD risk asso-
ciated both with MetS and with ED. Since these mar-
kers of subclinical atherosclerosis were most evident
among subjects with both MetS and ED, especially
t h e s ep a t i e n t ss h o u l db ec o n s i d e r e da th i g hc a r d i o v a s -
cular risk.
One mechanism linking MetS to ED is believed to be
hypogonadism associated with visceral obesity [53]. In
addition, physical activity may partly intermediate its
benefits through an induced increase in testosterone
levels [54]. Another possible pathophysiologic linkage
between MetS and ED is subclinical inflammation [55].
We did not assess testosterone or CRP levels which was
a limitation of the study.
IIEF questionnaire is a reliable method to assess the
presence and severity of ED [56]. In our study, number
of subjects reported lack of sexual activity and thus
were unable to answer the IIEF questions concerning
erectile function during intercourse. Among them, we
used a single-question assessment of ED. Although the
single-question assessment has been found to properly
identify men with ED [57], we wanted to be sure that
subjects participating in the study truly had either com-
pletely normal erectile function or real ED. Therefore,
we accepted only men with either full score or score
≤25 in the six-question IIEF or men with full score or
score ≤3 in the single-question assessment to participate
in the study. Because of the relatively small number of
study subjects and the fact that a single-question assess-
ment of ED was used among subjects without previous
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Page 7 of 9sexual activity, we could not study the effects of severity
of ED.
Conclusions
Increased fibrinogen and resting heart rate as well as
impaired arterial elasticity associated with the presence
of ED and were most evident among subjects with both
MetS and ED. Physical exercise, on its part, was a strong
and independent predictor of normal erectile function
among all as well as among only MetS subjects. Thus,
especially MetS patients presenting with ED should be
considered at high risk for CVD. In addition, our find-
ings support the importance of physical exercise in the
management of MetS and concomitant diseases.
Acknowledgements and Funding
We sincerely acknowledge Kalevi Oksanen, Päivi Kankkunen, Paula Lahtinen,
Kirsti Inkilä, Annika Palomäki, Sanna Haavisto and Outi Vanha-Kämppä for
their professional technical aid. The authors gratefully acknowledge the co-
operation of the study subjects.
The study was supported by grants from the Ministry of Health and Social
Welfare in Finland through the Medical Research Fund of Kanta-Häme
Central Hospital, the Häme and Pohjois-Savo Regional Funds under the
auspices of the Finnish Cultural Foundation, and Oy Eli Lilly Finland Ab.
None of them had a role in data collection, analysis of the results, or
preparation of the manuscript.
Author details
1Department of Emergency Medicine, Kanta-Häme Central Hospital,
Ahvenistontie 20, FI-13530, Hämeenlinna, Finland.
2Department of
Cardiometabolic Research, Linnan Klinikka, Raatihuoneenkatu 10, FI-13100,
Hämeenlinna, Finland.
3Heart Center, Kuopio University Hospital, PL 1777, FI-
70211 Kuopio, Finland.
Authors’ contributions
AP designed the study. HPM and AP participated in the acquisition and
analysis of the data. HPM, AP and JH participated in the drafting of the
manuscript. All authors have approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 March 2011 Accepted: 27 June 2011
Published: 27 June 2011
References
1. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis.
Physiol Rev 2004, 84:1381-1478.
2. Kirby M, Jackson G, Simonsen U: Endothelial dysfunction links erectile
dysfunction to heart Disease. Int J Clin Pract 2005, 59:225-229.
3. Cohn J, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J:
Non-invasive Pulse Wave Analysis for the Early Detection of Vascular
Disease. Hypertension 1995, 26:503-508.
4. Boutouyrie P, Tropeano I, Asmar R, Gautier I, Benetos A, Lacolley P,
Laurent S: Aortic stiffness is an independent predictor of primary
coronary events in hypertensive patients. A longitudinal study.
Hypertension 2002, 39:10-15.
5. Van Popele N, Grobbee D, Bots M, Asmar R, Topouchian J, Reneman R,
Hoeks A, Van der Kuip D, Hofman A, Witteman J: Association between
arterial stiffness and atherosclerosis. The Rotterdam study. Stroke 2001,
32:454-460.
6. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R,
Collen D, Muls E, Van de Werf F: Circulating oxidized LDL is a useful
marker for identifying patients with coronary artery disease. Arterioscler
Thromb Vasc Biol 2001, 21:844-848.
7. Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of
major cardiovascular diseases and nonvascular mortality: an individual
participant meta-analysis. JAMA 2005, 294:1799-1809.
8. Cooney M, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham I:
Elevated resting heart rate is an independent risk factor for
cardiovascular disease in healthy men and women. Am Heart J 2010,
159:612-619.
9. Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, Montorsi P,
Montorsi F, Vlachopoulos C, Kloner R, Sharlip I, Miner M: Erectile
dysfunction and coronary artery disease prediction: evidence-based
guidance and consensus. Int J Clin Pract 2010, 64:848-857.
10. Thompson I, Tangen C, Goodman P, Probstfield J, Moinpour C, Coltman C:
Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005,
294:2996-3002.
11. Inman B, Sauver J, Jacobson D, McGree M, Nehra A, Lieber M, Roger V,
Jacobsen S: A population-based, longitudinal study of erectile
dysfunction and future coronary artery disease. Mayo Clin Proc 2009,
84:108-113.
12. Araujo A, Hall S, Ganz P, Chiu G, Rosen R, Kupelian V, Travison T, McKinlay J:
Does erectile dysfunction contribute to cardiovascular disease risk
prediction beyond the Framingham risk score. J Am Coll Cardiol 2010,
55:350-356.
13. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Rigatti P,
Montorsi F: The artery size hypothesis: a macrovascular link between
erectile dysfunction and coronary artery disease. Am J Cardiol 2005,
96(Suppl):19M-23M.
14. Sisson SB, Camhi SM, Church TS, Martin CK, Tudor-Locke C, Bouchard C,
Earnest CP, Smith SR, Newton RL Jr, Rankinen T, Katzmarzyk PT: Leisure
time sedentary behaviour, occupational/domestic physical activity and
metabolic syndrome in U.S. men and women. Metab Syndr Relat Disord
2009, 7:529-536.
15. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, for the
DECODE study group: Prevalence of the metabolic syndrome and its
relation to all-cause and cardiovascular mortality in nondiabetic
European men and women. Arch Intern Med 2004, 164:1066-1067.
16. Third report of the National Cholesterol Education Program (NCEP) expert
panel on: detection, evaluation and treatment of high blood cholesterol
in adults (Adult Treatment Panel III) Final report. Circulation 2002,
106:3143-3421.
17. Ainsworth B, Haskell W, Whitt M, Irwin M, Swartz A, Strath S, O’Brien W,
Basset D, Schmitz K, Emplaincourt P, Jacobs D, Leon A: Compendium of
physical activities: an update of activity codes and MET intensities. Med
Sci Sports Exerc 2000, 32:498-516.
18. Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A: The
international index of erectile function (IIEF): a multidimensional scale
for assessment of erectile dysfunction. Urology 1997, 6:822-830.
19. Prisant LM, Pasi M, Jupin D, Prisant ME: Assessment of repeatability and
correlates of arterial compliance. Blood Press Monit 2000, 7:231-235.
20. Resnick LM, Militianu D, Cunnings AJ, Pipe JG, Evelhoch JL, Soulen RL,
Lester MA: Pulse waveform analysis of arterial compliance: relation to
other techniques, age, and metabolic variables. Am J Hypertens 2000,
13:1243-1249.
21. Wilson AM, O’Neal D, Nelson CL, Prior DL, Best JD, Jenkins AJ: Comparison
of arterial assessments in low and high vascular disease groups. Am J
Hypertens 2004, 17:285-291.
22. Zimlichman R, Shargorodsky M, Boaz M, Duprez D, Rahn KH, Rizzoni D,
Payeras AC, Hamm C, McVeigh G: Determination of arterial compliance
using blood pressure waveform analysis with the CR-2000 system:
reliability, repeatability, and establishment of normal values for healthy
European population - the seven European sites study (SESS). Am J
Hypertens 2005, 18:65-71.
23. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB: A
prospective study of risk factors for erectile dysfunction. J Urol 2006,
176:217-221.
24. Kratzik CW, Lackner JE, Märk I, Rücklinger E, Schmidbauer J, Lunglmayr G,
Schatzl G: How much physical activity is needed to maintain erectile
function? Results of The Androx Vienna Municipality study. Eur Urol 2009,
55:509-517.
25. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F,
D’Armiento M, Giugliano D: Effect of lifestyle changes on erectile
Pohjantähti-Maaroos et al. BMC Cardiovascular Disorders 2011, 11:36
http://www.biomedcentral.com/1471-2261/11/36
Page 8 of 9dysfunction in obese men. A randomized controlled trial. JAMA 2004,
291:2978-2984.
26. Teles AG, Carreira M, Alarcão V, Sociol D, Aragüés JM, Lopes L,
Mascarenhas M, Costa JG: Prevalence, severity, and risk factors for erectile
dysfunction in a representative sample of 3,548 Portuguese men aged
40 to 69 years attending primary healthcare centers: results of the
Portuguese erectile dysfunction study. J Sex Med 2008, 5:1317-1324.
27. Christensen BS, Grønbaek M, Pedersen BV, Graugaard C, Frisch M,
Horansanli K, Boylu U, Kendirci M, Miroglu C: Associations of unhealthy
lifestyle factors with sexual inactivity and sexual dysfunctions in
Denmark. J Sex Med 2011.
28. Hadaegh F, Zabetian A, Khalili D, Safarkhani M, James WP, Azizi F: A new
approach to compare the predictive power of metabolic syndrome
defined by a joint interim statement versus its components for incident
cardiovascular disease in Middle East Caucasian residents in Tehran. J
Epidemiol Community Health 2010.
29. Bal K, Öder M, Şahin A, Karataş C, Demir Ö, Can E, Gümüş B, Özer K,
Şahin O, Esen A: Prevalence of metabolic syndrome and its association
with erectile dysfunction among urologic patients: metabolic
backgrounds of erectile dysfunction. Urology 2007, 69:356-360.
30. Selvin E, Burnett AL, Platz EA: Prevalence and risk factors for erectile
dysfunction in the US. Am J Med 2007, 120:151-157.
31. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM: Beta-
blocker therapy and symptoms of depression, fatigue, and sexual
dysfunction. JAMA 2002, 288:351-357.
32. Düsing R: Effect of the angiotensin II antagonist valsartan on sexual
function in hypertensive men. Blood Press Suppl 2003, 2:29-34.
33. Doğru MT, Başar MM, Simşek A, Yuvanç E, Güneri M, Ebinç H, Batislam E:
Effects of statin treatment on serum sex steroids levels and autonomic
and erectile function. Urology 2008, 71:703-707.
34. Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and
leukocyte count: findings from the Third National Health and Nutrition
Examination Survey. Atherosclerosis 2003, 168:351-358.
35. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN: Relative
associations of fitness and fatness to fibrinogen, white blood cell count,
uric acid and metabolic syndrome. Int J Obes 2002, 26:805-813.
36. Myint PK, Luben RN, Wareham NJ, Welch AA, Bingham SA, Khaw KT:
Physical activity and fibrinogen concentrations in 23,201 men and
women in the EPIC-Norfolk population-based study. Atherosclerosis 2008,
198:419-425.
37. Sinha S, Luben RN, Welch A, Bingham S, Wareham NJ, Day NE, Khaw KT:
Fibrinogen and cigarette smoking in men and women in the European
Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk)
population. Eur J Cardiovasc Prev Rehabil 2005, 12:144-150.
38. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C,
Alexopoulos N, Stefanadi E, Askitis A, Stefanadis C: Unfavourable
endothelial and inflammatory state in erectile dysfunction patients with
or without coronary artery disease. Eur Heart J 2006, 27:2640-2648.
39. Pohjantähti-Maaroos H, Palomäki A, Kankkunen P, Laitinen R,
Husgafvel S, Oksanen K: Circulating oxidized low-density lipoproteins
and arterial elasticity: comparison between men with metabolic
syndrome and physically active counterparts. Cardiovasc Diabetol
2010, 9:41.
40. Ge JY, Li XL, Zhang HF, Xu Q, Tong M, Wang JG: Elasticity indices of large
and small arteries in relation to the metabolic syndrome in Chinese. Am
J Hypertens 2008, 21:143-147.
41. Kaya C, Ergelen M, Ilktac A, Karaman I: Impaired elasticity of aorta in
patients with erectile dysfunction. Urology 2007, 70:558-562.
42. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Tsekoura D,
Vasiliadou C, Stefanadi E, Askitis A, Stefanadis C: Arterial function and
intima-media thickness in hypertensive patients with erectile
dysfunction. J Hypertens 2008, 26:1829-1836.
43. Pohjantähti-Maaroos H, Palomäki A: Comparison of metabolic syndrome
subjects with and without erectile dysfunction - levels of circulating
oxidised LDL and arterial elasticity. Int J Clin Pract 2011, 65:274-280.
44. Kaiser D, Billups K, Mason C, Wetterling R, Lundberg J, Bank A: Impaired
brachial artery endothelium-dependent and -independent vasodilation
in men with erectile dysfunction and no other clinical cardiovascular
disease. J Am Coll Cardiol 2004, 43:179-184.
45. Yavuzgil O, Altay B, Zoghi M, Gürgün C, Kayıkçıoğlu M, Kültürsay H:
Endothelial function in patients with vasculogenic erectile dysfunction.
Int J Cardiol 2005, 103:19-26.
46. Sugawara J, Inoue H, Haysashi K, Yokoi T, Kono I: Effect of low-intensity
aerobic exercise training on arterial compliance in postmenopausal
women. Hypertens Res 2004, 27:897-901.
47. Elosua R, Molina L, Fito M, Arquer A, Sanchez-Quesada JL, Covas MI,
Ordonez-Llanos J, Marrugat J: Response of oxidative stress biomarkers to
a 16-week aerobic physical activity program, and to acute physical
activity, in healthy young men and women. Atherosclerosis 2003,
167:327-334.
48. Miyachi M, Kawano H, Sugawara J, Takahashi K, Hayashi K, Yamazaki K,
Tabata I, Tanaka H: Unfavorable effects of resistance training on central
arterial compliance. A randomized intervention study. Circulation 2004,
110:2858-2863.
49. Muñoz MD, Olcina G, Timón R, Robles MC, Caballero MJ, Maynar M: Effect
of different exercise intensities on oxidative stress markers and
antioxidant response in trained cyclists. J Sports Med Phys Fitness 2010,
50:93-98.
50. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van
Zwieten PA: The sympathetic nervous system and the metabolic
syndrome. J Hypertens 2007, 25:909-920.
51. Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif JC: Resting heart rate:
a modifiable prognostic indicator of cardiovascular risk and outcomes?
Can J Cardiol 2008, 24(SupplA):3A-8A.
52. Tomiyama H, Hashimoto H, Tanaka H, Matsumoto C, Odaira M, Yamada J,
Yoshida M, Shiina K, Nagata M, Yamashina A, baPWV/cfPWV Collaboration
Group: Synergistic relationship between changes in the pulse wave
velocity and changes in the heart rate in middle-aged Japanese adults:
a prospective study. J Hypertens 2010, 28:687-694.
53. Corona G, Mannucci E, Forti G, Maggi M: Hypogonadism, ED, metabolic
syndrome and obesity: a pathological link supporting cardiovascular
diseases. Int J Androl 2009, 32:587-598.
54. Revnic CR, Nica AS, Revnic F: The impact of physical training on
endocrine modulation, muscle physiology and sexual functions in
elderly men. Arch Gerontol Geriatr 2007, 44(Suppl 1):339-342.
55. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C: Inflammation,
metabolic syndrome, erectile dysfunction and coronary artery disease:
common links. Eur Urol 2007, 52:1590-1600.
56. Cappelleri J, Rosen R, Smith M, Mishra A, Osterloh I: Diagnostic evaluation
of the erectile function domain of the international index of erectile
function. Urology 1999, 54:346-351.
57. O’Donnell AB, Araujo AB, Goldstein I, McKinlay JB: The validity of a single-
question self-report of erectile dysfunction. Results from the
Massachusetts Male Aging Study. J Gen Intern Med 2005, 20:515-519.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/11/36/prepub
doi:10.1186/1471-2261-11-36
Cite this article as: Pohjantähti-Maaroos et al.: Erectile dysfunction,
physical activity and metabolic syndrome: differences in markers of
atherosclerosis. BMC Cardiovascular Disorders 2011 11:36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pohjantähti-Maaroos et al. BMC Cardiovascular Disorders 2011, 11:36
http://www.biomedcentral.com/1471-2261/11/36
Page 9 of 9